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Abstract Background: Attention-deficit hyperactivity disorder (ADHD) is a common
psychiatric disorder in childhood, affecting 3–7% of school-age children in
the US and imposing substantial economic burden. Stimulants are considered
first-line pharmacological treatment and are the most prescribed treatment
for ADHD. However, approximately 30% of children with ADHD do not have
an optimal response to a single stimulant and may require adjunctive therapy.
Objective:Our objective was to conduct a cost-effectiveness analysis (CEA) of
adding a non-stimulant, guanfacine extended release (GXR), to stimulants
versus maintaining existing stimulant monotherapy in the treatment of
ADHD in children and adolescents with suboptimal response to stimulant
monotherapy.
Methods: A 1-year Markov model was developed to estimate costs and ef-
fectiveness from a US third-party payer perspective. Effectiveness was mea-
sured by the QALY. The model assumed that patients transitioned among
four health states (normal, mild, moderate and severe), defined by the Clinical
Global Impression-Severity (CGI-S) scale. Transition probabilities were es-
timated in an ordered logit model using patient-level data from a multicentre,
9-week, double-blind, placebo-controlled, dose-optimization study, where
subjects (n = 461) continued their stable morning stimulant and were ran-
domized to GXR administered in the morning, GXR administered in the
evening, or placebo. The model assumed that patients in moderate/severe
health states after week 8 would discontinue ADHD treatment and remain in
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that state for the rest of the study period. Direct costs included drug wholesale
acquisition costs and health state costs, all in $US, year 2010 values. Utility
associated with each health state was obtained from the literature and dis-
utilities associated with adverse events were applied for the first 4 weeks. One-
way sensitivity analyses and probabilistic sensitivity analysis (PSA) were
conducted by varying costs, utilities, adverse-event duration, and transition
probabilities.
Results:Compared with maintaining existing stimulant monotherapy, adding
GXR to existing stimulant monotherapy was associated with an incremental
drug cost of $US1016 but a lower medical cost of $US124, resulting in a total
incremental cost of $US892 at 1 year. The addition of GXR to stimulants led
to an incremental QALY of 0.03 and an incremental cost-effectiveness ratio
(ICER) of $US31 660/QALY. In one-way sensitivity analysis, ICER values
ranged from$US19723, when 100% of patients were assumed to be severe in their
initial health state, to $US46631, when the last observed states from the clinical
trial were carried forward to the end of the 1-year analysis period. PSA demon-
strated a 94.6% likelihood that the ICER falls below $US50000/QALY.
Conclusions: The impairment associated with residual ADHD symptoms
after stimulant therapy is becoming increasingly recognized. This is the first
analysis of the cost effectiveness of stimulants combined with an adjunctive
medication. This study suggests that the adjunctive therapy of GXR with
stimulants is a cost-effective treatment based on a willingness-to-pay thresh-
old of $US50 000/QALY. This may address an unmet need among patients
with suboptimal response to stimulant monotherapy.
Key points for decision makers
 Some paediatric attention-deficit hyperactivity disorder (ADHD) patients receiving stimulant
treatment alone present with suboptimal symptom control
 Adjunctive treatment with guanfacine extended release (GXR) addresses an unmet need of
this group of ADHD patients by improving their symptom control
 Adjunctive treatment withGXR in this ADHDpatient population appears cost effective, addressing
an unmet need among ADHD patients with suboptimal response to stimulant monotherapy
Background
Attention-deficit hyperactivity disorder (ADHD)
is a common psychiatric disorder in childhood
and adolescence, affecting 3–7% of school-age
children in the US.[1,2] ADHD is characterized by
symptoms of hyperactivity, impulsivity and in-
attention, which interfere with a child’s ability to
function at school and at home.[3,4]
ADHD substantially impairs the quality of life
of affected children and adolescents as well as
their family members.[5] It also poses considerable
economic burden to the healthcare system and
society worldwide. In the US, total healthcare
costs for children and adolescents with ADHD
have been estimated to be $US7.9 billion dollars
per year (year 2005 values).[6] The indirect costs
for ADHD related to education, criminality and
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caregiver work loss are even more striking.[6-8]
Costs associated with education and criminality
among school-aged children with ADHD have
been estimated to be $US34.6billion per year (year
2005 values). In addition, adult family members
of children and adolescents with ADHDmay incur
an additional $US4.9 billion in indirect costs an-
nually (year 2000 values).[7] In the Netherlands,
mean 1-year costs per patient with ADHD were
h2040 and the mean excess annual indirect cost due
to absence from and decreased productivity at work
of mothers of ADHD patients was h1835 (year
2004 values).[9] In Belgium, annual private medical
costs for a child with ADHD are more than six
times the costs for a sibling control; annual societal
medical costs for a child with ADHD are double
the costs for a sibling control.[10] In addition, in
some countries, such as Germany, treatment costs
associated with ADHD have been increasing.[11]
Effective treatment of ADHD may reduce the
psychosocial and economic burden associated with
the disease. Disease management usually involves
some combination of behaviour modification,
lifestyle changes, counselling and medication. Stim-
ulants, such as amphetamine and methylpheni-
date, are the mainstays of pharmacological therapy
and are first-line treatment options for the ma-
jority of patients with ADHD.[3] However, based
on a systematic literature review and pooling
of randomized controlled trials of children aged
6–12 years, on average, approximately 30% of
children with ADHD do not have an adequate
response to the stimulant methylphenidate.[12]
Patients with suboptimal response to stimulants
present a unique challenge in the management of
ADHD. Alternative treatment options may in-
clude non-stimulants indicated for ADHD (e.g.
atomoxetine, guanfacine extended release [GXR]
or clonidine extended release) and some medica-
tions that are not approved by the US FDA for
ADHD (such as tricyclic antidepressants, bupro-
pion, guanfacine immediate release and clonidine
immediate release), as well as adding adjunctive
pharmacotherapy to the existing stimulants. Ad-
junctive therapy may help further improve the
core ADHD symptoms that cannot be fully con-
trolled by stimulants alone. Therefore, it could be
a practical treatment option among patients with
suboptimal response to stimulants.[13] While in-
formation regarding the use of adjunctive ther-
apy with stimulants in children/adolescents with
ADHD is scarce, a retrospective claims-based
analysis found that 21% of adult patients on long-
acting stimulants used adjunctive therapy for the
treatment of ADHD.[14] Despite the relatively high
prevalence of adjunctive therapy among stimu-
lant users, there are limited clinical trial data to
support the combination use of a stimulant and
another medication. In fact, many commonly used
adjunctive medications, such as bupropion, cloni-
dine immediate release and guanfacine immediate
release, are not approved for the treatment of
ADHD by the FDA.
To date, the only once-daily FDA-approved
medication for adjunctive therapy to stimulants is
GXR. GXR is not yet approved in the EU; how-
ever, there are two clinical trials currently ongoing
in the EU.[15,16] GXR is a selective alpha-2A
adrenergic receptor agonist and was approved by
the FDA in September 2009 as monotherapy for
the treatment of ADHD in children and adoles-
cents aged 6–17 years. The mechanism of action
of guanfacine in the treatment of ADHD is un-
known. Preclinical research suggests that guan-
facine strengthens working memory and prefrontal
cortex neuronal firing. In clinical trials, GXR has
demonstrated efficacy and tolerability both as
a monotherapy and as an adjunctive therapy
to stimulants.[17-19] In a phase II open-label trial
of GXR as an adjunctive therapy to stimulants
(methylphenidate or amphetamine), no unique
adverse events (AEs) were observed with GXR
given with a stimulant compared with those re-
ported historically for either treatment alone.[18]
Recently, results from a phase III, double-blind,
randomized, placebo-controlled, multicentre, dose-
optimization study evaluated the efficacy and
tolerability of GXR as adjunctive therapy to stim-
ulants in children and adolescents aged 6–17 years
with ADHD and suboptimal response to stimu-
lant monotherapy.[20,21] Significant reductions in
ADHD symptoms were reported for subjects re-
ceiving GXR, when dosed either in the morning
or in the evening, in addition to the existing stim-
ulant, compared with maintaining the existing
stimulant in the same patient population.[20,21]
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The cost effectiveness of GXR as an adjunctive
therapy to stimulants has not been explored.
While adding GXR to stimulants has the poten-
tial to increase pharmacy costs and AEs asso-
ciated with ADHD treatment due to the need
for two pharmacological agents, it is associated
with better clinical outcomes than stimulant mono-
therapy among patients with suboptimal response
to stimulants.[20] To fully understand the eco-
nomic value of GXR as an adjunctive therapy, we
conducted a cost-effectiveness analysis (CEA) of
GXR as an adjunctive therapy to existing stimu-
lants compared with maintaining existing stimulant
monotherapy among children and adolescents with




We designed a Markov model to evaluate the
cost effectiveness of GXR as an adjunctive ther-
apy to stimulants compared with stimulant
monotherapy in the treatment of ADHD in chil-
dren and adolescents with suboptimal response
to stimulants. The model was created from a US
third-party payer perspective with a 1-year time
horizon, which has been commonly used in other
CEAs of ADHD treatments.[12,22,23]
Patient-level data from the phase III random-
ized, double-blind clinical trial comparing GXR
as adjunctive therapy to stimulants with placebo
plus stimulants were used to estimate the transi-
tion probabilities among health states, the initial
distribution of health states, and the AE rates for
each treatment arm.[20,21,24] In addition, data ex-
tracted from a literature review provided inputs
for utilities, medical costs and disutilities asso-
ciated with AEs.
Phase III Trial of Guanfacine Extended
Release as an Adjunctive Therapy
to Stimulants
The phase III, 9-week, double-blind, randomized,
placebo-controlled, multicentre, dose-optimization
study evaluated the efficacy and safety of GXR
(1, 2, 3 and 4mg/day) plus stimulants compared
with placebo plus stimulants in children and
adolescents with ADHD aged 6–17 years with
suboptimal response to stimulants.[21] Suboptimal
response to stimulants was defined as treatment
with a stable dose of stimulant for at least 4 weeks
with improvement; however, mild to moderate
ADHD symptoms must have remained present (an
ADHD Rating Scale Version IV [ADHD-RS-IV]
score of ‡24 and a Clinical Global Impression-
Severity [CGI-S] score of ‡3) or an investiga-
tor assessment of inadequate response to current
psychostimulant must have been given.[20,21]
Subjects with no response to stimulants prior to
study enrolment were excluded from participat-
ing in this study. The study included a 5-week
dose-optimization period for GXR, followed by a
3-week dose-maintenance period and a 1-week
dose-tapering period. This design took into account
the prompt onset of effects for most ADHD
medications.[21]
In the trial, a total of 461 patients were random-
ized; however, only 455 of the randomized patients
received at least one dose of study medication and
constituted the full analysis set (FAS)/safety pop-
ulation: 150 patients received GXR in the morning,
152 received GXR in the evening, and 153 received
placebo, all of whom continued their stable dose of
stimulant throughout the trial.[21] The FAS/safety
population dataset was used in this study.
The primary efficacy outcome was a change
in ADHD-RS-IV total score from baseline to
endpoint, defined as the last on-therapy, post-
baseline treatment week prior to any dose taper
at which a valid ADHD-RS-IV total score was
collected. Secondary outcomes included the CGI-S
and AE outcomes.[21]
The mean age of the trial population was 10.8
years. The trial population was 71.6% male.[21]
The majority of study subjects were in the mod-
erate health state (see the Model Description
section for a description of the health states) at
baseline, accounting for 90.5% of the total trial
population. Patients in the mild and severe states
accounted for 3.5% and 5.9%, respectively.[24]
To be consistent with the GXR package insert,
this study compared the combined GXR treat-
ment arms (evening and morning) with the pla-
cebo arm.[20]
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Model Description
The Markov model consisted of four health
states reflecting the severity of ADHD symptoms
– normal, mild, moderate and severe (figure 1) –
with a cycle length of 1 week. The cycle length
reflected the frequency of efficacy assessment in
the phase III trial. The health states were defined
based on the CGI-S. The CGI-S is a 7-point scale
designed for clinicians to rate the severity
of a patient’s condition and is a common end-
point in clinical trials evaluating new treatments
for ADHD. It ranges from 1 (‘not ill at all’) to 7
(‘among the most extremely ill subjects’). In our
study, the normal state was defined as a CGI-S
score of 1, i.e. ‘not ill at all’; the mild state was
defined as a CGI-S score of 2 or 3, i.e. ‘borderline
ill’ or ‘mildly ill’; themoderate state corresponded to
a CGI-S score of 4 or 5, i.e. ‘moderately ill’ or
‘markedly ill’; and lastly, the severe state was
defined as a CGI-S score of 6 or 7, i.e. ‘severely ill’
or ‘among the most extremely ill subjects’. Strat-
ification with four health states could better dif-
ferentiate patients by level of symptoms than with
two health states (i.e. response vs non-response),
which have been used in previous ADHD cost-
effectiveness literature.[22,25] Because the four
health states have not been defined in the litera-
ture based on the ADHD-RS-IV scale, the CGI-S
was used in this study in order to be consistent
with the definition of health states used in the
study from which ADHD health utility values
were extracted.[26]
A hypothetical cohort of children and adoles-
cents with ADHD received GXR plus stimulants
or placebo plus stimulants at the model entry and
transitioned between the four health states at the
beginning of each cycle. The initial distribution
among the health states was determined based on
the observed distribution of the phase III trial
population at baseline. The model consisted of two
stages. The first stage was modelled to span from
week 0 to week 8, and the second stage spanned
from week 9 to week 52. All patients continued
their assigned treatments during the first stage. In
the second stage, patients in the moderate or se-
vere states were considered to be non-responsive
and thus permanently discontinued the treat-
ments. Because most of the patients in the trial
were in the moderate or severe state at baseline,





















































































Fig. 1. Diagram of health states. Patients may enter the model in the mild, moderate or severe states. The data in the tables represent the
various transition probabilities. GXR =guanfacine extended release; SE = standard error.
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being in the moderate or severe state at week 8
would indicate a lack of response to treatment.
The two-stage assumption was consistent with
the approach used in the technology assessment
conducted by the National Institute for Health
and Clinical Excellence (NICE),[22] which as-
sumed that children who did not respond to the
initial therapy by week 8 would not continue the
original treatment. In addition, the assumption
was also supported by a real-world adherence
study, which showed that the majority of patients
with ADHD were compliant with treatment for
an average of 2 months.[27]
Model Assumptions
The assumptions made were as follows:
 Modelled patients were in one of the four health
states in each cycle (normal, mild, moderate or
severe) and could transition into a less or more
severe state at the beginning of each cycle of
the model.
 Patients followed the transition probabilities
during the trial period as long as they were on
treatment.
 Patients who transitioned into the moderate or
severe state during the second stage discontinued
treatment and remained in the last health state
while on treatment for the rest of the model
period.
 Patients who discontinued treatment remained
off treatment and did not switch to new treat-
ments. Therefore, the model assumed that these
patients only incurred medical costs for the rest
of the model period. Subsequent therapies were
not included in the model for two reasons:
(i) there was insufficient clinical evidence or
consensus on how patients would be treated
after failing combination therapy; and (ii) choices
of subsequent therapies would be different for
the two treatment arms. For example, patients
in the stimulant monotherapy arm could use
GXR as an adjunctive therapy while this was
not an option for patients in the GXR plus
stimulants arm. If different subsequent therapies
were assumed for the two comparison arms,
the final outcomes would reflect the effects of
both the initial therapy and subsequent thera-
pies, which was not the objective of the current
study.
 The health utility corresponding to each health
state did not depend on treatment, i.e. regard-
less of whether a patient was on treatment
or not and the type of treatment, patients in




Transition probabilities were calculated based
on patient-level data from the phase III trial.
Following the trial definition of the endpoint, we
used the efficacy data from the first 8 weeks. The
weekly endpoint measure was defined as in the
trial, as the last on-therapy, post-randomization
treatment week, prior to any dose taper, at which
a valid ADHD-RS-IV total score was collected.
Patients were assigned each week to one of the
four health states from week 0 to week 8 based on
the observed weekly CGI-S values.[24] To be
consistent with the trial protocol, missing values
were imputed using the last observation carried
forward (LOCF).
In the base-case model, we used ordered logit
models to estimate the transition probabilities,
where the dependent variable was the current
health state and the independent variable was the
health state in the previous week. By estimating
transition probabilities in this way, we assumed
that health status in one state was purely a func-
tion of health state in the previous state. In addition,
patients’ transitions between health states in the
eight time periods were assumed to be constant
(e.g. time independent). Transition probabilities
were estimated for the placebo plus stimulants
arm and the combined GXR plus stimulants arm.
The estimated transition probabilities were ap-
plied throughout the entire 52-week model period
for patients remaining on treatment (see figure 1).
Costs
Because the CEA was conducted from a US
third-party payer perspective, only direct costs
were estimated, which included treatment drug
costs and medical costs. All cost inputs were ex-
tracted from public data or literature and were
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inflation-adjusted to $US, year 2010 values using
the medical care component of the Consumer
Price Index[28] (table I).
The wholesale acquisition cost (WAC)[30] was
used as the unit cost for GXR and stimulants. If a
drug had different doses, the average WAC among
all available doses was estimated. The stimulants
used in the model were consistent with what was
observed in the phase III trial, which included
Adderall XR (mixed salts of a single-entity
amphetamine product extended release; Shire
Pharmaceuticals, Inc.,Wayne, PA,USA), Vyvanse
(lisdexamfetamine dimesylate; Shire Pharmaceu-
ticals, Inc., Wayne, PA, USA), Concerta
(methylphenidate hydrochloride [HCl]; Ortho-
McNeil-Janssen Pharmaceuticals, Inc., Raritan,
NJ, USA), Focalin XR (dexmethylphenidate
HCl extended release; Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA), Ritalin
LA (methylphenidate HCl long acting; Novartis
Pharmaceuticals Corporation, East Hanover,
NJ, USA), and Metadate CD (methylphenidate
HCl, United States Pharmacopeia [USP], con-
trolled delivery; UCB, Inc.; Brussels, Belgium).
Most patients in the trial were taking either
Concerta (45%) or Vyvanse (29%). The final
unit cost for stimulants was estimated as a weighted
Table I. Key model inputs
Model input Value Source
Initial health state distribution (%)




Weekly medical costs ($US)a

























Percentage of patients taking stimulant (%)









a Costs are in year 2010 values.
b Intuniv: GXR.
c Adderall XR: mixed salts of a single-entity amphetamine
product extended release.
d Concerta: methylphenidate HCl.
e Focalin XR: dexmethylphenidate HCl extended release.
f Metadate CD: methylphenidate HCl, USP, controlled delivery.
g Ritalin LA: methylphenidate HCl long acting.
h Vyvanse: lisdexamfetamine dimesylate.
ADHD =attention-deficit hyperactivity disorder; AWP =average
wholesale price; GXR =guanfacine extended release; HCl =hydro-
chloride; USP =United States Pharmacopeia; WAC =wholesale
acquisition cost.
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average of WACs based on the distribution of
stimulants observed in the trial. We assumed that
patients took one dose of stimulants and GXR
per day as per the trial design.
Medical costs by disease severity among pa-
tients with ADHD have not been studied. Medi-
cal cost inputs used for this study were derived
based on a retrospective cohort study comparing
healthcare costs between children with ADHD
and those without ADHD in a health mainte-
nance organization in western Washington state
in the US.[29] In this study, children had a mean
age of 11.7 years and 77.2% were male. Of the pa-
tients with ADHD, 28.7% had co-morbid mental
health conditions (11.1% internalizing condi-
tions, 12.3% externalizing conditions, 3.6% sub-
stance abuse/dependence).
To account for the skewed distribution of
healthcare costs and ensure that higher costs were
assigned to more severe states, we assumed that
the annual medical costs for patients in the nor-
mal state were the same as median medical costs
for non-ADHD patients ($US374); the annual
medical costs for patients in the mild state were
the same as the median medical costs for ADHD
patients ($US944); the annual medical costs
for patients in the moderate state were the same
as the mean medical costs for ADHD patients
($US1601); and the annual medical costs for
patients in the severe state were the ones for the
moderate state plus the medical cost difference
between the mild and moderate states ($US2259).
All annual costs were divided by 52 weeks to es-
timate costs per cycle (table I).
Utilities
Utilities Associated with Health States
Utility values were obtained from a recent
study by Lloyd et al.[26] In our model, health states
based on the CGI-S were defined in the same way
as those from Lloyd et al., with the exception that
the severe state in their study excluded the most
severe CGI-S state 7, ‘among the most extremely
ill subjects’. The utility data were collected from a
survey of 100 members of the general public in
the UK. Both a time trade-off (TTO) method and
a visual analogue scale (VAS) were used to esti-
mate the utilities associated with the four health
states. Utility values estimated from the TTO
method were used in this study. The means and
standard errors of the utilities for normal, mild,
moderate and severe states were 0.839 (0.020),
0.787 (0.022), 0.578 (0.028) and 0.444 (0.023),
respectively.
Disutilities Associated with Adverse Events
In addition to utility associated with each
health state, disutilities associated with AEs were
also applied. AEs were included if they impacted
at least 5% of patients in any treatment arm and
were listed on the product insert.[20] AE rates were
obtained from observed rates for each treatment
arm during the phase III trial (table II).[20,24] This
assumed that no new AEs would occur after the
trial period. In the base case, disutilities associated
with AEs were applied for the first 4 weeks after
treatment initiation. Disutility values associated
with these AEs were identified from a literature
review.[31-34] The total disutility values associated
with these AEs were 0.265 and 0.123 for the GXR
plus stimulants and stimulant monotherapy
treatment arms, respectively.
Model Outputs
Model outputs included cost and effectiveness
outcomes for each treatment arm, incremental
cost, incremental effectiveness, and incremental
cost-effectiveness ratio (ICER) comparing GXR
plus stimulants with stimulant monotherapy.
Total direct costs were estimated by summing
direct costs across all model cycles. Both total
direct costs and costs for each component
(ADHD drug costs and medical costs) were esti-
mated. Incremental costs were estimated as the
cost differences per patient between the two
treatment arms during the model period. QALYs
were estimated as the sum of the weighted time
spent in each cycle for the 1-year model period,
using the utility for each cycle as the weight. In-
cremental effectiveness was estimated as the
QALY difference per patient between the two
treatment arms. Finally, the ICER was estimated
as the ratio between incremental cost and incre-
mental effectiveness and was expressed as an in-
cremental cost per QALY.
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Sensitivity Analysis
To test the model’s robustness, key parameters
and model assumptions were varied using one-way
sensitivity analyses on transition probabilities,
costs, utilities, AE duration, stimulant choice,
and initial state distribution.
 Transition probabilities: Instead of a modelling
approach, we used the observed transitions be-
tween the health states during the first stage (i.e.
the first 8 weeks). We further assumed that
health states were stabilized without further
transitions in the second stage (i.e. week 9 to
week 52) and carried forward the week-8 health
states until the end of the model period.
 Drug costs: The average wholesale prices
(AWPs) were used to estimate the unit costs
for ADHD medications instead of the WACs.
Furthermore, costs for stimulants were varied by
assuming 100% of patients were onRitalin LA,
Adderall XR, Vyvanse, or Metadate CD.
 Medical costs: We varied the cost of each
health state by setting the cost equal to that of
the next less severe health state or the cost equal
to that of the next more severe health state.
For the lower bound of the cost for a normal
patient, we used the cost of a normal patient
minus 25%. For the upper bound of the cost
for a severe patient, we used the cost of a severe
patient plus 25%. We also considered a scenario
where medical costs were assumed to be zero.
 Utility values: The utility values for the health
states were varied to the upper and lower
bounds of the 95% confidence intervals (CIs)
reported in the study by Lloyd et al.[26] The
utilities corresponding to the upper bound of
the 95%CI for the normal, mild, moderate and
severe states were 0.880, 0.830, 0.633 and
0.504, respectively. The utilities corresponding
to the lower bound of the 95% CI for the
normal, mild, moderate and severe states were
0.799, 0.744, 0.523 and 0.385, respectively.[26]
 AEs: Disutilities associated with AEs were ap-
plied for 0, 2 and 8 weeks, respectively.
 Initial patient distribution: The initial distri-
bution of patients was assumed to be 100%
mild, 100% moderate and 100% severe.
A multivariate probabilistic sensitivity ana-
lysis (PSA) was also conducted with a Monte
Carlo simulation of 1000 iterations.Model inputs
with uncertainties were included in the PSA, in-
cluding transition probabilities, the medical cost
of each health state, the utility of each health state,
and the duration of AEs. For transition prob-
Table II. Adverse eventsa
AE GXR plus stimulants (%) Stimulants only (%) Disutilityb,c Source
Headache 21 13 0.353 Revicki and Wood[31]
Somnolenced 18 7 0.380 Heeg et al.[32]
Insomniae 12 6 0.324 Botteman et al.[33]
Fatigue 10 3 0.380 Heeg et al.[32]
Abdominal painf 10 3 0.040 Kristiansen et al.[34]
Dizziness 8 4 0.461 Revicki and Wood[31]
Decreased appetite 7 4 0.048 Revicki and Wood[31]
Nausea 5 3 0.048 Revicki and Wood[31]
a AEs that impacted at least 5% of any treatment arm were included. In the base case, AEs were assumed to result in utility decrements
lasting 4 weeks.
b Disutility data were taken from the Tufts CEA Registry.[35]
c The disutility associated with fatigue was assumed to equal somnolence. The disutility from dizziness was assumed to equal
lightheaded/faint. The disutility from decreased appetite was assumed to equal nausea.
d The somnolence term included somnolence, sedation and hypersomnia.
e The insomnia term included insomnia, initial insomnia and middle insomnia.
f The abdominal pain term included abdominal pain, abdominal pain upper and abdominal pain lower.
AE = adverse event; CEA = cost-effectiveness analysis; GXR = guanfacine extended release.
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abilities, probabilities of remaining in the same
health state were included as a random variable
with Beta distribution bounded by 0 and 1.
Transition probabilities to other health states
were re-estimated based on the ratios between
these probabilities in the base case and the new
probability of remaining in the same health state
in the PSA. The calculations ensure that transi-
tion probabilities from a given health state to all
four states sum to one. For medical costs and
utilities, the inputs for the normal state were in-
cluded as random variables. Gamma distribution
was used for the cost variable assuming that the
mean cost equalled the standard deviation; Beta
distribution bounded by 0 and 1 was used for the
utility variable. To ensure that medical costs in-
crease with disease severity and utilities decrease
with disease severity, the values for each other state
(i.e. mild, moderate and severe) were re-estimated
by applying the ratio between that state and the
normal state in the base case to the new value
for the normal state in the PSA. In addition, the
durations of all AEs were varied simultaneously by
randomly drawing from a Uniform distribution
from 0 to 8 weeks. The ICER values at 1 year were
plotted in a cost-effectiveness acceptability curve
(CEAC), from which the probability of GXR plus
stimulants being cost effective compared with pla-
cebo plus stimulants was assessed based on differ-
ent willingness-to-pay (WTP) thresholds.
Results
Base-Case Analysis
Adding GXR as an adjunctive therapy to stim-
ulants was associated with $US1016 higher costs
for ADHDpharmacymedication costs ($US1690
vs $US675) but $US124 less in medical costs
($US1297 vs $US1421), leading to a total in-
cremental cost of $US892 ($US2987 vs $US2095)
compared with stimulant monotherapy. The com-
bination therapy also increased QALYs by 0.028
(0.655 vs 0.627). Excluding the impact of AEs led to
a QALY difference of 0.031 (0.660 vs 0.629). As a
result, the ICER was $US31660/QALY for treat-
ment with GXR as an adjunctive therapy to stimu-
lants comparedwith stimulantmonotherapy among
children and adolescents with ADHD who had a
suboptimal response to stimulants (table III).
Sensitivity Analysis
Results from the one-way sensitivity analyses
showed that the ICER ranged from $US19 723/
QALY, when all patients were assumed to start
in the severe state, to $US46 631/QALY, when
transition probabilities as observed in the trial
were applied and patients were assumed not to
transition beyond week 8 (figure 2). Overall, the
results were sensitive to the assumptions for
transition probabilities, initial health state dis-
tribution, and unit drug costs. All ICERs from
the sensitivity analyses were within +/-20% of the
base-case value, with the exception of the follow-
ing three assumptions: (i) transition probabilities
as observed in the trial, (ii) 100% of patients start-
ing with the severe health state, and (iii) AWPs as
unit drug costs. When no medical cost offsets
were assumed by using more efficacious treat-
ment, the ICER increased from $US31 660/
QALY to $US36 065/QALY. The PSA demon-
strated a 94.6% likelihood that the ICER was less
than $US50 000/QALY. The median ICER was
shown to be $US32720/QALY with a 95% CI of
$US17338/QALY to $US54938/QALY (figure 3).



















2095 675 1421 0.627 0.629 Reference Reference Reference
GXR plus
stimulants
2987 1690 1297 0.655 0.660 892 0.028 31660
a Costs are in year 2010 values.
AE = adverse event; GXR =guanfacine extended release; ICER = incremental cost-effectiveness ratio.
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Discussion
The current CEA evaluated the cost effectiveness
of GXR as an adjunctive therapy to stimulants
compared with stimulant monotherapy among
children and adolescents with ADHD who had
suboptimal response to stimulants. The base-case
analysis showed that although adding GXR as an
adjunctive therapy increased ADHD drug costs,
the costs could be partially offset by the differ-
ence in medical costs. In addition, the combina-
tion of GXR and stimulants led to, on average,
0.028 higher QALYs than stimulants alone. While
the disutility associated with AEs was higher
for those patients taking GXR and stimulants
because of the added pharmacotherapy, this was
offset by the increases in utility associated
with symptom improvements. With the ICER of
$US31660/QALY, GXR as an adjunctive therapy
to stimulants would be considered as cost effec-
tive at a WTP threshold of $US50 000/QALY.
The one-way sensitivity analyses conducted in
our study found that the results were most sensi-
tive to the assumptions about the transition
probabilities. When the transition probabilities
observed in the trial were used and patients were
assumed not to transition beyond week 8, the
model generated the highest ICER of $US46 631/
QALY. This is not surprising as we assumed that
the impact of the combination therapy was limited
to only within the trial period – a conservative
assumption against combination therapy. Other
drivers of the results included the distribution of
health states at the model entry and unit ADHD
Initial state distribution − 100% severe










































10 000 20 000 30 000
ICER ($US/QALY)
40 000 50 000
AWP price for Intuniv®1 and stimulants
Initial state distribution − 100% mild
No medical costs
AE duration − 8 weeks
AE duration − 0 weeks
Cost of moderate equals severe
Cost of moderate equals mild
Utilities (upper 95% CI)
Stimulant composition − 100% Ritalin LA®2
Utilities (lower 95% confidence level)
Cost of mild equals moderate
AE duration − 2 weeks
Cost of mild equals normal
Stimulant composition − 100% Adderall XR®3
Cost of normal equals mild
Stimulant composition − 100% Vyvanse®4
Initial state distribution − 100% moderate
Disutilities +25%
Disutilities −25%
Stimulant composition − 100% Concerta®5
Cost of severe equals moderate
Cost of severe +25%
Cost of normal −25%
1 Intuniv®: GXR.
2 Ritalin LA®: methylphenidate HCl long acting.
3 Adderall XR®: mixed salts of a single-entity amphetamine product extended release.
4 Vyvanse®: lisdexamfetamine dimesylate.
5 Concerta®: methylphenidate HCI.
28 989
Fig. 2. Univariate sensitivity analysis. The base-case incremental cost-effectiveness ratio is $US31 660/QALY. AE =adverse event; AWP =
average wholesale price; CI= confidence interval; GXR = guanfacine extended release; HCl =hydrochloride; ICER = incremental cost-effec-
tiveness ratio; LOCF = last observation carried forward;WTP =willingness to pay.
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drug costs. However, none of the ICERs exceeded
$US50 000/QALY. It is worth mentioning that
although assumptions had to be made to estimate
medical costs associated with each health state,
the results were not sensitive to these assump-
tions. Even if we completely eliminated the med-
ical costs in the model estimation, the ICER was
similar to the base-case value. While there is
substantial debate in the US surrounding the use
of cost effectiveness for decision making, CEAs
are increasingly being used to support formulary
reimbursement and tier status placement.[36] A
review of published CEAs demonstrated that 34%
mentioned an explicit threshold, with the median
threshold of $US50 000/QALY.[37] However, re-
cent research demonstrates that a threshold of
$US50000/QALY is likely significantly lower than
the WTP threshold within the US for a QALY,
which is more likely between $US100 000 and
$US300000.[38] Therefore, the use of a $US50000/
QALY threshold can be seen as a lower bound for
the value of a QALY, implying that even under
conservative assumptions, GXR as an adjunctive
therapy to stimulants is good value for themoney.[39]
Suboptimal response to stimulants is not un-
common among children and adolescents with
ADHD.[1,12,40] These patients may be difficult to
treat because they have fewer FDA-approved treat-
ment options after stimulant therapy. The clinical
evidence on the efficacy and safety of pharma-
cological treatment in suboptimal responders
to stimulants is limited. GXR has demonstrated
efficacy and tolerability among children and ado-
lescents with ADHD and suboptimal response to
stimulants.[17-19] It is the only once-daily ADHD
medication approved by the FDA as an adjunc-
tive therapy to stimulants. The economic evi-
dence on combination therapy is scarce. Given
that GXR has recently received regulatory ap-
proval as an adjunctive therapy, the study pro-
vides timely information to physicians and payer
decision makers about the economic value of
adding GXR to stimulants.
Comparison with Other Studies
While many studies have evaluated the cost
effectiveness of stimulants both compared with
no treatment and compared with other stimu-
lants,[12,22,25] no study has evaluated the cost
effectiveness of non-stimulants as an adjunctive
therapy. Two studies have evaluated treatment
strategies in patients with ADHD who had a
suboptimal response to stimulants. A study by
Faber et al.[41] found that the stimulant osmotic-
release oral system (OROS) methylphenidate was
a cost-effective treatment for patients in the
Netherlands whose response to methylphenidate
immediate release (MPH-IR) was suboptimal.
This study differed from ours in a number of ways.
First, the target population in the study by Faber
et al.[41] included patients with suboptimal re-
sponse to MPH-IR, while the target population in
our study consisted of patients with suboptimal
response to a group of different stimulants, in-
cluding amphetamine andmethylphenidate, all of
which are long-acting medications. Second, Faber
et al.[41] defined a suboptimal response as the sub-
optimal response due to patient non-compliance.
Third, the two studies were conducted in two
countries with vastly different healthcare systems.
Therefore, the results between the two studies are
not directly comparable. A separate study by
Prasad et al.[23] examined the cost effectiveness of
atomoxetine compared with dexamfetamine in





















































































Fig 3. Cost-effectiveness acceptability curve comparing stimulant
monotherapy with stimulant and adjunctive therapy of guanfacine
extended release. GXR =guanfacine extended release; ICER =
incremental cost-effectiveness ratio.
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analysed the cost effectiveness of a non-stimulant in
a difficult-to-treat patient population, it did not
consider atomoxetine as an adjunctive therapy to
stimulants. In addition, the CEA in the study by
Prasad et al.[23] was conducted in a different target
population, including patients who failed both
MPH-IR and methylphenidate extended release,
and in a different healthcare setting. These differ-
ences prevent us from directly comparing the results
with those from our study.
Limitations
First, this economic evaluation used aMarkov
model framework. Markov models assume that a
patient’s disease course can be captured in tran-
sitions between different health states. While this
may be an oversimplification of the real-world
disease course, it is a commonly used approach
and often necessary when the time horizon in the
model extends beyond the clinical trial period.
Although the Markov model used in this study
may not fully reflect health states and transitions
in the real world, it better differentiated ADHD
severity than models used in previous CEAs, which
only classified patients as responders or non-
responders.[22,25] In addition, using the current
model structure, the distribution of health states
at week 8 was similar to the one observed in the
phase III trial.[21] In the placebo plus stimulants
arm, the proportion of patients in the normal,
mild, moderate and severe states based on the
model estimation were 13.2%, 51.1%, 34.2% and
1.5%, respectively, compared with 15.1%, 46.7%,
36.2% and 2.0%, respectively, as observed in the
trial. In the GXR plus stimulants arm, the pro-
portion of patients in the normal, mild, moderate
and severe states based on the model estimation
were 21.4%, 56.4%, 21.8% and 0.4%, respectively,
compared with 23.9%, 53.2%, 21.9% and 1.0%,
respectively, as observed in the trial.[21]
Second, other limitations involve the assump-
tions made in the model implementation. For
example, we assumed that patients discontinued
treatment if they transitioned into the moderate
or severe state during the second stage. Although
not all patients follow this treatment rule in the
clinical setting, this may be a realistic assumption
because most patients achieve optimal dosing
within 8 weeks. If patients do not respond or lose
response during an 8-week treatment, they may
have limited benefit from continuing treatment
and be considered for alternative therapies. Such
an assumption was also implemented in a previous
CEA of treatments for ADHD.[22] In addition,
we assumed that patients who discontinued
treatment did not switch to other therapies. Al-
though this assumption deviates from the clinical
setting, it is necessary for our results to reflect
only the outcome difference between the two
treatments of interest and not be confounded by
the subsequent therapies.
Third, the model estimation is limited by data
availability. Because costs associated with differ-
ent health states have not been reported, we had
to make assumptions based on existing studies to
estimate these model inputs. The decision rule
for assigning cost values to each health state was
relatively arbitrary. However, results from the
one-way sensitivity analyses showed that the re-
sults were not sensitive to the assumptions used
to estimate costs for each health state. Even if we
conservatively assumed that all medical costs
were zero, the ICER was still similar to the base-
case value. Furthermore, data from different studies
were applied in the model with the underlying
assumption that the populations in these studies
were comparable. However, the populations on
which the model inputs were based were often
different. To address this limitation, various sensi-
tivity analyses were conducted to test the robust-
ness of the results. Overall, our model results
were not sensitive to cost and utility inputs.
Fourth, the study used data from the phase III
clinical trial to estimate the effectiveness out-
comes. To be enrolled in the clinical trial, patients
were required to meet specific inclusion and ex-
clusion criteria. For example, the trial excluded
patients who have any current, controlled or un-
controlled, co-morbid psychiatric diagnosis (ex-
cept oppositional defiant disorder). Of the patients
in the FAS/safety population, 19.8% had a diagnosis
of oppositional defiant disorder at baseline.[24]
The real-world effectiveness may be affected by
patient compliance and co-morbidities. There-
fore, the study findings may not be generalizable
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to a real-world setting. Future studies with esti-
mated transition probabilities based on the real-
world effectiveness data are needed. In addition,
our study only considered patients taking long-
acting stimulants and therefore the results may
not be generalizable to patients taking im-
mediate-release stimulant formulations.
Finally, this study was conducted from a US
third-party payer perspective and did not include
indirect cost estimates associated with parent and
caregiver work loss, additional educational re-
sources, and crime and delinquency. A study by
Pelham et al.[6] found that healthcare costs asso-
ciated with ADHD in children and adolescents
account for approximately 19% of the total cost
burden of ADHD; the remainder is associated
with educational costs (32%) and crime and de-
linquency costs (50%). If the indirect costs were
added into the model, then the ICER may have
been even lower than the current result.
Conclusions
The impairment associated with residual ADHD
symptoms after stimulant therapy and the need to
optimize treatment are becoming increasingly
recognized. This is the first analysis to estimate the
cost effectiveness of stimulants combined with an
adjunctive medication. The current economic
evaluation indicates that GXR as an adjunctive
therapy to stimulants is cost effective compared
with stimulant monotherapy among children and
adolescents with ADHD and a suboptimal re-
sponse to stimulants. GXR as an adjunctive ther-
apy could be a practical option to address the
unmet needs of this patient population. In addi-
tion, findings from this study may better inform
physicians and payer decision makers about the
value of this new treatment for children and
adolescents with ADHD, while assessing poten-
tial cost implications as well.
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